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Rivastigmine modiﬁes the α-secretase pathway
and potentially early Alzheimer’s disease
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Abstract
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate
Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1)
and γ-secretase endoproteolysis. Alternative APP cleavage by α-secretase (a family of membrane-bound
metalloproteases– Adamalysins) precludes the generation of toxic Aβ and yields a neuroprotective and neurotrophic
secreted sAPPα fragment. Several signal transduction pathways, including protein kinase C and MAP kinase, stimulate
α-secretase. We present data to suggest that rivastigmine, in addition to anticholinesterase activity, directs APP
processing away from BACE1 and towards α-secretases. We treated rat neuronal PC12 cells and primary human brain
(PHB) cultures with rivastigmine and the α-secretase inhibitor TAPI and assayed for levels of APP processing products
and α-secretases. We subsequently treated 3×Tg (transgenic) mice with rivastigmine and harvested hippocampi to
assay for levels of APP processing products. We also assayed postmortem human control, AD, and AD brains from
subjects treated with rivastigmine for levels of APP metabolites. Rivastigmine dose-dependently promoted α-secretase
activity by upregulating levels of ADAM-9, -10, and -17 α-secretases in PHB cultures. Co-treatment with TAPI eliminated
rivastigmine-induced sAPPα elevation. Rivastigmine treatment elevated levels of sAPPα in 3×Tg mice. Consistent with
these results, we also found elevated sAPPα in postmortem brain samples from AD patients treated with rivastigmine.
Rivastigmine can modify the levels of several shedding proteins and directs APP processing toward the nonamyloidogenic pathway. This novel property of rivastigmine can be therapeutically exploited for disease-modifying
intervention that goes beyond symptomatic treatment for AD.

Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia and the ﬁfth leading cause of death in the
elderly1. Deposition of the amyloid-β (Aβ) peptide of
4.2 kDa within the brain parenchyma and hyperphosphorylation of the microtubule-associated protein, tau
(MAPT) of 42–47 kDa, are cardinal neuropathologies of
AD2,3. To generate Aβ, a type 1 integral membrane protein, APP, is sequentially cleaved by β-secretase 1
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(BACE1) into two fragments: secreted APPβ (sAPPβ) and
a membrane-bound cytoplasmic tail fragment β (CTFβ) of
99 amino acids, which is further processed by γ-secretase,
a complex of four integral membrane subunits. Aβ
secreted from cultured cells varies in length from 36 to 43
amino acids). Overall processing of APP to Aβ and subsequent risk of AD is a product of genetic and environmental inﬂuences that can coalesce through epigenetic
processes4,5. Aβ is normally secreted into cell culture
media, cerebrospinal ﬂuid, plasma and the vitreous
humor6, but it represents a minor fraction of peptides
derived from γ-secretase cleavage of APP. Instead, the
majority of APP is processed by α-secretase at a site
within the Aβ peptide sequence to a longer secreted APPα
(sAPPα) and CTFα (83 amino acids), which is further
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cleaved by γ secretase to create a shorter 3 kDa fragment,
P3. Alterations in levels of Aβ, P3, and other APP processing products can accompany other causes of dementia, such as normal pressure hydrocephalus (NPH)7.
Hence, redirection of APP processing towards the αsecretase pathway may be of potential therapeutic value in
AD. Therefore, in this article, we demonstrate a noncholinergic property for the anti-AD drug rivastigmine.
Speciﬁcally, rivastigmine reduces Aβ generation by
directing APP processing towards the neuroprotective
pathway dominated by the α-secretase pathway.
The primary α-secretases are known as ADAMs (A Disintegrin And Metalloproteases), a family of integral membrane proteins with roles that drive the ectodomain
shedding of key transmembrane proteins such as the Notch
receptor, APP, TNF-α, ErbB2, and ErbB48. Notably,
ADAM-9, -10 and -17 are involved in the cleavage of APP
as a redundant family of α-secretases. ADAM-17 is also
involved in the shedding of pro-TNF-α to produce TNF-α,
and can, therefore, regulate this important proinﬂammatory pathway9. ADAM-17 inhibitor (BMS
561392) treatment does not increase levels of Aβ peptides10.
This is most likely due to distinct compartmentalization of
APP by transport to the cell membrane (location of αsecretase processing) or endosomes (location of β-secretase
processing)11.
Rivastigmine (aka, ENA 713/carbamoylatine), an FDAapproved acetyl- and butyryl-cholinesterase inhibitor
(AChEI/BuChEI), is used to treat mild-moderate AD by
elevating synaptic acetylcholine (ACh) levels, under the
trademark “Exelon”. As of 2015, at least 13 double-blind
clinical trials of rivastigmine efﬁcacy for AD12 demonstrated the agent to be beneﬁcial for mild-to-moderate
AD, as compared to placebo. In addition, rivastigmine has
been involved in 137 studies registered with the US
National Library of Medicine as of the composition of this
paper. These include not only symptomatic relief for AD,
but also potential treatment of post-operative delirium,
amnestic mild cognitive impairment (MCI), Down syndrome, cocaine and amphetamine dependence, and Parkinson’s disease, among others13. Although rivastigmine is
a dual cholinesterase inhibitor (ChEI), it more efﬁciently
binds BuChE than AChE14. It has been suggested that
preserving levels of extracellular acetylcholine through
inhibiting BuChE could play an important role in treating
AD15. However, evidence has emerged that rivastigmine
may not merely be symptom-ameliorating but may provide disease-modifying activity16–18.
While rivastigmine is approved as a ChEI, it may be that
its overall efﬁcacy involves acting on other pathways. We
have previously demonstrated that select ChEIs possess
APP-modulating properties19, but such action appears to be
via mechanisms distinct from their cholinergic activities.
For example, the ChEI (−)-Phenserine and its
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cholinergically inert opposite enantiomer (+)-Phenserine
(posiphen) both have APP and Aβ lowering properties in
cell culture, animal models20, and AD subjects21. In addition, donepezil elevates sAPPα and reduces Aβ in culture by
upregulating sorting nexin protein 33 (SNX33)22. Rivastigmine also elevated sAPPα and lowers levels of Aβ in a
rodent primary culture system, as well as enhancing levels
of axonal markers such as synaptosomal-associated protein25 (SNAP25)17. Herein we employed a diverse but integrated approach to test our hypothesis, which included (i)
rat neuronal PC12 cultures, (ii) primary human brain (PHB)
cultures23, (iii) triple-transgenic AD model mice, and (iv)
postmortem human brain samples from AD patients who
had not been exposed to rivastigmine, patients treated with
rivastigmine, and non-AD age-matched controls (Fig. 1).
Rivastigmine induced a dose-dependent shift toward αsecretase processing of APP in PHB cultures and transgenic
animals. This shift was also reﬂected in postmortem human
brain samples collected from subjects treated with
rivastigmine-associated change. We characterized this as a
shift in processing because levels of overall APP were not
altered by rivastigmine. In addition, we measured effects of
rivastigmine on the ADAM α-secretase proteins and
observed increases in levels of proproteins and mature
proteins. Our results demonstrate that rivastigmine can
modify levels of the active form of several α-secretases and
redirect APP processing to the non-amyloidogenic pathway.
This supports the notion that rivastigmine potentially possesses disease-modifying activity and opens the door to
investigate rivastigmine derivatives that have low ChEI
activity to potentially support higher dosing without the
accompanying undesired effects of modifying cholinesterase
(ChE) activity. Rivastigmine’s non-cholinergic effects on AD
have not been reported much in literature speciﬁc to AD
patient outcomes. We interpret this to mean that rivastigmine’s non-cholinergic effects would not be expected to
be evident at stages where the drug would be prescribed.
Rivastigmine is prescribed to treat mild-to-moderate
dementia. The consensus of the ﬁeld is that such stages
may be too late to apply disease-modifying treatments24–26.
We contend, in agreement with this trend, that any diseasemodifying outcomes associated with rivastigmine have been
effectively hidden by the disease stages in which the drug is
typically prescribed.
In the present work, we demonstrate rivastigmine’s
novel property of directing APP processing into the nonamyloidogenic pathway in a comprehensive manner, utilizing relevant cell cultures, transgenic animal model, and
human samples from extreme ends of the lifespan (Fig. 1).

Materials and methods
Rivastigmine

Rivastigmine was provided as a gift by Dr. Martin
Farlow (Indiana University School of Medicine) as
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Fig. 1 Overview of the study and Research workﬂow. This report used four complementary materials and workﬂows to elucidate rivastigmine
activity. a Interrelations of APP pathway metabolites and biomarkers (some are studied herein). Brieﬂy, hAPP serves as substrate for several enzymes.
Among these are the ADAM proteins, which begin as their proADAM protein counterparts, which are cleaved by Furin. hAPP is also cleaved by BACE1.
The cleavages of hAPP produce the protein/peptide products sAPPα, sAPPβ, CTFα, and CTFβ. The total of sAPPα and sAPPβ, along with minor
cleavage products, produce sAPPt. Cleavage of CTFα and CTFβ by γ-secretase complex produces P3 from CTFα, Aβ40 and Aβ42 from CTFβ, and
AICD50 from both CTFα and CTFβ. In addition, the CTG assay assesses overall cell culture health. b Rat pheochromocytoma (PC12) cell cultures were
neuronally differentiated with NGF and then treated with Rivatigmine and TAPI, alone and in combination in media. Conditioned media (CM) was
collected and cells were harvested and lysed. Lysate was used to assess cell culture health by CTG, while CM was assayed for protein and peptide
levels by western blot (WB) and ELISA. c Primary human brain (PHB) cultures were grown according to protocols developed in our laboratory. PHB
cultures were treated with rivastigmine and TAPI, alone and in combination. CM was collected and cells harvested and lysed. Culture health was
assessed by CTG, and both lysates and CM were used in western blots and ELISA. d Female 3 × Tg mice were grown to 6 months and injected IP with
rivastigmine or saline. Hippocampus was harvested and lysed to use in western blots and ELISA. e Donated human autopsy brain tissue was collected
from patients who had AD without drug treatment, AD with rivastigmine treatment, and non-AD subjects. Tissues were lysed and levels of peptides
and proteins assayed by ELISA.

1.5 mg (rivastigmine tartrate) pharmaceutical capsules.
Capsule contents were suspended in sterile water and
disrupted by sonication. Suspensions were clariﬁed by
centrifugation to yield 5 mM stock solution. Other
capsule contents included hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, and
silicon dioxide, generally considered pharmaceutically
inert27. Concentration of stock solution was veriﬁed by
comparison to analytical standards (Novartis, East
Hanover, NJ) by UV-Vis spectrometry with Nanodrop
spectrophotometer (ThermoFisher Scientiﬁc, Waltham,
MA)
Neuronally differentiated pheochromocytoma (PC12) cell
culture

PC12 cells were obtained from ATCC, and cultured as
described in our previous work28. Cells were differentiated by exposure to nerve growth factor (NGF)
(30 ng/ml) (Sigma) for 3 days in low (1%) serum containing RPMI1640 medium (ThermoFisher). Cell

cultures were routinely assessed for mycoplasma contamination by use of a commercially available assay. STR
proﬁling was not routinely performed over the course of
these experiments. For cell culture experiments, sample
size was determined by multiple previous works in cell
culture reasonable sample sizes for our APP and other
assays29–32.
Drug treatments of differentiated PC12

On culture day 12, media were removed from differentiated PC12 cells, and different doses of rivastigmine (5,
10, and 20 µM) were mixed with fresh medium and added
to the wells. Four additional wells were treated with
10 μM TAPI. Four further wells were co-treated with 10
or 20 μM of rivastigmine and 10 μM TAPI. After 4 days of
drug treatment, conditioned media (CM) samples were
collected and stored at −80 °C. Cells were then washed
once with ice cold PBS, lysed by addition of mammalian
protein extraction reagent (M-PER buffer, Pierce), and
supplemented with protease inhibitor cocktail (Roche).
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Cell lysate (CL) samples were used for Cell Titer Glow
(CTG, Promega) assays.
Primary PHB culture

PHB cultures were prepared from the brain tissue of
aborted fetuses (80–100 days gestational age). Tissue was
obtained from the Birth Defects Research Laboratory (BDRL)
of the University of Washington, Seattle, WA. BDRL is in
compliance with all relevant State and Federal regulations.
IRB approvals to handle and process such materials were
obtained from Indiana University School of Medicine
(IUSM), Indianapolis. Materials (10–20 g) were shipped to
IUSM overnight in chilled Hibernate-E medium (Invitrogen),
supplemented with B27 cell culture supplement, GlutaMax,
and an antibiotics mixture. Cell culture procedures followed
our previously described protocols23. Brieﬂy, tissue was
placed in a trypsin EDTA tube and kept on a shaking water
bath (150 RPM) at 37 °C for 15 min. The trypsin-digested
tissue was transferred to Hibernate-E medium in a 15 mL
PET and triturated using a siliconized, ﬁre-polished pipette
several times followed by centrifugation at 400 × g for 15 min.
The cell pellet was resuspended in Hibernate-E medium
followed by one more trituration and centrifugation. The
resulting pellet was resuspended in culture medium and cell
counting was performed by the Trypan blue exclusion
method. The cells were plated on poly-D-lysine coated 24well plates in neurobasal medium, supplemented with 1×
B27 + 0.5 mM glutamax + 5 ng/mL bFGF + antibiotics
cocktail (neuro+). Half of the medium was replaced by fresh
medium + supplements on every 4th day. We have previously established that PHB cultures grown under these
conditions to produce a mixture of neuronal and astrocytic
cells on culture day 2031. We, thus, consider them a sufﬁciently good working model for human brain cell studies. For
cell culture experiments, sample size was determined by
multiple previous works in cell culture reasonable sample
sizes for our APP and other assays29–31.
Drug treatments of PHB cultures

On the 20th culture day, medium was pipetted off PHB
cultures and different doses of rivastigmine (100 nM, 1 µM,
and 10 µM) were mixed with fresh neurobasal medium and
added to wells. Four additional wells were treated with 10 μM
TAPI. Four further wells were co-treated with 10 μM rivastigmine and 10 μM TAPI. Drug treatments were undertaken
over 4 days and (Supplementary Fig. S1), after treatment, CM
samples were collected and stored at −80 °C. Cells were then
washed once with ice cold PBS, lysed by addition of M-PER
buffer (Pierce), and supplemented with protease inhibitor
cocktail (Roche). CL samples were used for the subsequent
Western immunoblotting and other assays (Fig. 1).
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Cell viability assays

Equal volumes of CL samples were pipetted into white
translucent 96-well plates (Corning) and an equal amount
of CTG reagent was added (Promega). Plates were
immediately placed on a shaker for 1 min followed by
incubation at room temperature for 10 min. Thereafter,
luminescence signals were recorded using a luminometer,
as described previously33.
Western blotting

CM protein samples were mixed with 2 × Laemmli
buffer, boiled for 5 min and equal volumes (12 μL) were
loaded onto a 26-well Criterion gel (BioRad) and electrophoresed for 1.2 h at 200 volts, then transferred onto a
PVDF membrane (BioRad). After blocking with 5% milk
in TBST, we probed with mAb6E10 antibody (BioLegend,
San Diego, CA) to evaluate sAPPα levels. After several
washes with TBST, the membrane was exposed 1 h to
anti-mouse secondary IgG followed by further washes
with TBST. Electrochemiluminescence (ECL) substrate
(Pierce) was added, followed by exposure to X-ray ﬁlm
band densities. Thereafter, western immunoblot “Reprobe
buffer” (Thermo) was added to the same strip of the
membrane. Following vigorous shaking for 10 min,
washes with TBST and blocking for 30 min with 5% milk,
the strip was probed for 45 min with anti-mouse secondary IgG and then exposed to X-ray ﬁlm to ensure that
the sAPPα primary antibody had been completely
removed. On conﬁrming this, the strip was used to
determine total sAPP band densities using mAb22C11
antibody (Chemicon). Western immunoblotting of the CL
samples was done with 22C11 (for intracellular full-length
APP), ADAM-9 (Sigma), ADAM-10 (Sigma), and ADAM17 (Enzo life science) antibodies. Films were scanned at 16
bits (grayscale), 300dpi, without tone or color correction.
Densitometry was measured by ImageJ34. CL signals were
normalized to β-actin signals from the same lane, while
CM and intracellular signals were analyzed without further normalization.
ELISA procedure

Sensitive ELISAs were used according to the manufacturer’s protocols. Equal volumes (25 μL) of CM samples were incubated in wells, pre-coated with anti-human
sAPPα antibody (2B3, from IBL America, Minneapolis,
MN). This kit used anti-human APP (R101A4) as a
detection antibody. Levels of Aβ peptides (1–40 and 42)
were quantiﬁed using commercially available kits (IBL).
For sAPPβ ELISA, anti-human sAPPβ-wild-type rabbit
IgG was applied as a capture and R101A4 utilized as a
detection antibody.
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Treatment of APP/PS1/tau Tg mice with rivastigmine

All experiments that used animals were reviewed and
approved before initiation by the Institutional Animal
Care and Use Committee (IACUC) of the Intramural
Research Program, National Institute on Aging (Protocol
No. 331-TGB-2021), which monitored all processes for
compliance with appropriate regulatory and ethical standards. 3×TgAD mice were generated from a presenilin-1
mutant (PS1M146V) mouse embryo that was transfected
with two expression plasmids: A cDNA encoding the
“Swedish” double mutation of APP (APPKM670/671NL)
and a tau mutation (MAPTP301L) that causes frontotemporal lobe dementia, both under the control of the
Thy-1 promoter35. The 3×TgAD mice used in the present
study had been backcrossed for 8 generations onto a
C57BL/6 background and developed Aβ and tau pathologies and behavioral deﬁcits over a longer time, compared
to the original 3×TgAD mice35. Female 3×TgAD mice
(weight range 26–46 g, 6 months) were randomized into
treatment and control groups by online utility (random.
org) and administered rivastigmine (0.75 mg/kg fresh in
physiological saline, 100 µl/10 gm body weight, via daily IP
injection for 21 days) or saline, respectively. The method
of euthanasia was anesthesia/suffocation by CO2 followed
by mechanical decapitation after complete unconsciousness, as checked by tail pinch method, consistent with the
recommendations of the American Veterinary Medical
Association. Animals were euthanized 90 min following
their ﬁnal dose, and their brains rapidly removed and
dissected on wet ice. Investigators were not blinded to
group allocation. We chose a sample size of ﬁve animals
per group and assumed an attrition rate of one animal,
which provided us with a worst-case of four animals per
group. This sample size had previously proved adequate
to detect Cohen’s d of >120,36.
Preparation of mouse brain lysates

Hippocampi were harvested from the mice by dissection
followed by snap freezing in liquid nitrogen and storage at
−80 °C until analysis. Secreted proteins from samples
were isolated as previously37 with minor modiﬁcation.
Brieﬂy, samples were homogenized in 50 mM NaCl, 0.2%
DEA using a Polytron homogenizer (Kinematica GmbH,
Germany), followed by centrifugation at 100,000 × g for
1 h. Supernatant (secreted fraction) was stored for analyses. M-PER buffer was added to pellet, sonicated brieﬂy,
and centrifuged at 13,000 × g for 15 min, then used to
analyze intracellular soluble proteins.
Analyses of mouse brain lysates

Protein concentration from secreted and intracellular
soluble fractions was estimated by Bradford Assay. Then
equal protein amounts of samples were loaded onto a
Bis-Tris minigel, and western immunoblotting was
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performed as described above. Levels of sAPPt and
sAPPα in the secreted fraction of the lysate were evaluated by using mAb22C11 and mAb6E10 antibodies,
respectively. Aβ in all mouse tissues was measured by
ELISA (IBL America)
Human postmortem brain tissue analyses

Human postmortem brain tissue samples were obtained
from the University of Kentucky Alzheimer’s Disease
Center biobank using methods described previously38,
and with IRB approvals from the University of Kentucky,
Lexington, KY, USA38. Informed consent or assent was
collected and is held at the University of Kentucky.
Potential subjects were excluded a priori if they had severe
neuropsychiatric or substance abuse disorders. Subjects
were excluded postmortem if the brain regions were in an
infarct or neoplasia (primary or metastatic) in the brain38.
Subjects were clinically evaluated on an annual basis, drug
use was monitored by self-report, and participants were
asked to bring their medicine containers with them to
each visit. Brain tissue samples were collected soon after
death (postmortem interval <5 h), and a subset of subjects
who were regularly treated with rivastigmine was identiﬁed. Samples were anonymized before distribution by the
biobank. Samples from individuals who did not have AD
or other neurological disorders are referred to as “nonAD controls” in this paper. A subsample of AD patients
who did not take any ChEI medications were also included in the study. Samples were all from Brodmann areas
21/22, also known as the middle and superior temporal
gyri. Following protein extraction, all samples were subjected to ELISA to evaluate levels of sAPPα, sAPPt and Aβ
peptides (both 1–40 and 42). The same methods were
employed as described above for the mouse brain lysates
to extract presumed secreted and intracellular fractions
from human postmortem brain tissue samples (Fig. 1).
Each brain specimen cohort had ﬁve specimens per group.
This sample size is sufﬁcient at power 85% to detect a
Cohen’s d of >2, with type I error rate (alpha) of 5%.
Statistical analyses

Results were analyzed with the R statistical language,
using generalized linear models (GLM)39 followed by analysis of deviance F test (ANODE/ANOVA) and simultaneous pairwise comparisons of estimated marginal
means40,41 if predictor variable was nominal. GLMs relax
assumptions of the traditional ANOVA, particularly
assumptions of “normal” distribution and homoscedasticity
(equal variances). Dose response analyses were on logtransformed µM dose + 1 to permit log(dose = 0) to be 0,
instead of “undeﬁned”. Effect sizes and calculations are
described in Supplemental Methods. Brieﬂy, FC: Foldchange, ΔFC: change of fold-change between rivastigmine
and rivastigmine + TAPI treatments.
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Results
Rivastigmine improved cell viability, and altered APP
metabolism in rodent-origin neuronally differentiated cell
cultures

We observed a signiﬁcant (p < 0.05) increase in
rivastigmine-treated PC12 cell viability, as measured by
CTG after rivastigmine treatment, whereas TAPI treatment reduced cell viability (Fig. 2a). When interaction of
rivastigmine and TAPI was tested, TAPI eliminated the
rivastigmine effect (Fig. 2b, p < 0.001 for interaction).
We measured levels of secreted APP metabolites from
the same samples. Rivastigmine treatment increased
sAPPα (Fig. 2c, d) and reduced sAPPβ and Aβ40 levels
(Fig. 2e–g) in CM samples. When we overlaid CTG,
sAPPα, sAPPβ, and Aβ data (Fig. 2h), sAPPα elevation
outstripped CTG gains, while Aβ40 and sAPPβ both
were reduced in a dose-dependent fashion. We concluded that the apparent elevation of sAPPα was not
likely to be solely due to overall increases in culture cell
number. TAPI treatment (Fig. 2i, j) reduced sAPPα
only-modestly in vehicle-treated controls, but fully
reversed the rivastigmine-stimulated sAPPα to levels
lower than untreated control cultures. ANOVAs are
summarized in Supplementary Table S1. We had previously determined that rivastigmine treatment of primary rat brain cell cultures (PRBC) substantially
preserved neuronal structure and protected neurons
from degeneration while maintaining levels of
neuronally-originated APP forms17.
Rivastigmine treatment did not alter levels of intracellular
full-length APP (holo-APP/hAPP) or total secreted APP
(sAPPt) in PHB cultures but altered several individual APP
processing product levels

We co-treated PHB cultures with Rivastigmine and TAPI
and performed western blot analysis of hAPP from PHB
lysates (Fig. 3a) and total secreted APP (sAPPt), and sAPPα
(Fig. 3b, c). The latter blots were of conditioned media and,
therefore, had no β-actin loading control. We performed
independent ELISA for levels of sAPPα, sAPPβ, cytoplasmic fragment β (CTFβ), Aβ40, and Aβ42, as well as
CTG assay. No signiﬁcant effects appeared for rivastigmine
or TAPI treatment on hAPP, nor for the interaction of
rivastigmine and TAPI (Fig. 3d, Supplementary Table S2).
Neither rivastigmine nor TAPI signiﬁcantly altered total
secreted APP (sAPPt) levels, but the interaction was signiﬁcant (Fig. 3e, Supplementary Table S2). In essence, the
very slight increase in sAPPt levels induced by rivastigmine
(+0.006 fold-change) was more than reversed by TAPI
treatment. By contrast, sAPPα (Fig. 3f, Supplementary
Table S2) signiﬁcantly increased (+0.138 FC/ + 0.039 FC)
following rivastigmine treatment and signiﬁcantly
decreased (−0.074 FC/−0.039 FC) after TAPI treatment by
both western blot and ELISA (Fig. 3g), and their interaction
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(ΔFC −0.175/−0.070) was also signiﬁcant in that TAPI
more than eliminated any rivastigmine effects. Separate
ELISA for sAPPβ, APP cytoplasmic fragment (CTF)β, and
Aβ40 and Aβ42 peptides (Fig. 3h–k, Supplementary Table
S2) revealed that rivastigmine treatment signiﬁcantly (p ≤
0.001) reduced all four of these β-secretase processing
products. TAPI did not induce a signiﬁcant effect on
sAPPβ, Aβ40, or Aβ42 in control cultures but it reversed
the rivastigmine-mediated reduction of these APP-derived
fragments. Cellular viability of PHB cultures (evaluated by
CTG assay) was unaltered following rivastigmine treatment. TAPI caused a small (−0.018 FC) but signiﬁcant
(p = 0.011) decline in cellular viability (Fig. 3l), but rivastigmine appeared to prevent TAPI toxicity.
Rivastigmine treatment elevated levels of sAPPt and sAPPα
in hippocampus of 3×Tg mice

Western immunoblot analyses of sAPPα (Fig. 4a) and
sAPPt (Fig. 4b) in M-PER buffer soluble intracellular extract
from hippocampal lysates of 3×Tg mice revealed that both
(Fig. 4c, d) were elevated upon rivastigmine treatment vs.
untreated mice. Likewise, the ratio of sAPPα to sAPPt was
elevated after Rivastigmine treatment (Fig. 4e).
Rivastigmine treatment decreased levels of intracellular
and secreted Aβ peptides in the hippocampus of 3xTg
mice

Quantiﬁcation of intracellular and secreted Aβ40 and
Aβ42 levels by ELISA revealed a decline in the hippocampus of rivastigmine-treated 3×Tg mice (Fig. 4f–g, i–j).
Rivastigmine did not affect the sAβ42 to total sAβ ratio
(Fig. 4h), but reduced the ratio of intracellular Aβ42
(iAβ42) to total iAβ (Fig. 4k).
Rivastigmine increased levels of mature ADAM-9, ADAM10, and pro-ADAM-10 in PHB cultures. TAPI increased
levels of ADAM-9 and pro-ADAM-10, but decreased levels
of mature ADAM-10

Western immunoblotting of CL samples from primary
PHB cultures (Fig. 5a) revealed signiﬁcant increases in
levels of intracellular mature ADAM-9 (Fig. 5d) and
ADAM-10 (Fig. 5e) in rivastigmine-treated samples vs
controls as well as signiﬁcant elevation in pro-ADAM-10
(Fig. 5b) levels. There was no evidence of change in proADAM-9 (Fig. 5b). TAPI treatment, on the other hand,
increased mature ADAM-9 (Fig. 5d) and pro-ADAM-10
(Fig. 5e), but resulted in signiﬁcant reduction of mature
ADAM-10 (Fig. 5e). Rivastigmine enhanced apparent
cleavage of ADAM-9 (Fig. 5f), while TAPI enhanced
cleavage of ADAM-9 (Fig. 5f) but signiﬁcantly diminished
maturation of ADAM-10 (Fig. 5g). ADAM-17 densitometry was saturated and unable to be reliably quantiﬁed
(Fig. 1). Two-way modeling of the data revealed that
several rivastigmine effects were altered by addition of
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(see ﬁgure on previous page)
Fig. 2 Effects of Rivastigmine and TAPI treatments on cell viability, Aβ40, and sAPPα in neuronally differentiated PC12 cells. Neuronally
differentiated PC12 cultures were treated in two separate experiments with rivastigmine (A, C–H) or rivastigmine plus TAPI (B, I–J). a Culture viability
assessed by CTG for Rivastigmine and TAPI. b CTG for Rivastigmine/TAPI co-treatment. c Western blot of sAPPα from PC12 cultures treated with three
doses of rivastigmine plus vehicle. d Densitometry of blot was analyzed by GLM vs rivastigmine dose. e Western blot of sAPPβ from PC12 cultures
treated with three doses of rivastigmine plus vehicle. f Densitometry of blot was analyzed by GLM vs rivastigmine dose. g Aβ40 from cells assayed
by ELISA. h Composite plot of relative levels of each biomarker in A, D, F, and G. i Western blot of sAPPα from rivastigmine/TAPI co-treatment.
j Densitometry of blot. Data from three blots were analyzed in J with mixed-level GLM, using random intercepts for each blot to account for inter-blot
variation. A representative blot is shown. Aβ40 was measured by rodent-speciﬁc ELISA.

Fig. 3 Effects of treatments on APP processing products and viability in human cultures, interaction effects. Primary human brain (PHB)
cultures were co-treated with rivastigmine and TAPI as described in the text. Figure shows effects of rivastigmine or TAPI alone. a Cell extracts were
prepared and probed for hAPP by western blot. b Conditioned media were analyzed on westerns probed separately for sAPPt, and c sAPPα. Blots
were analyzed by semiquantitative densitometry. Figure shows combined effects of rivastigmine and TAPI. Densitometry analysis for d hAPP, e sAPPt,
and f sAPPα. Different ELISAs were used to assay levels of g sAPPα (ELISA), h sAPPβ, i CTFβ, j Aβ40, and k Aβ42. l Cell viability was assessed with CTG.

TAPI. Notably, TAPI signiﬁcantly interfered with rivastigmine vs. precursor and mature ADAM-9 and 10
(Fig. 5a–e). TAPI reversed rivastigmine effects on
maturation of ADAM-9 (Fig. 5e), but not ADAM-10
maturation (Fig. 5f). ANOVA outcomes summarized in
Supplementary Table S3.

Rivastigmine treatment associated with increased levels of
sAPPα in postmortem brain samples

Analyses of postmortem brain tissue extracts revealed
no changes in sAPPt (Fig. 6a) but a signiﬁcant rise in
sAPPα (Fig. 6b) in samples from patients treated with
rivastigmine vs. those who had not received any AD
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Fig. 4 Effects of Rivastigmine on sAPPt, sAPPα, and Aβ levels in hippocampus of 3xTg mice. Alzheimer’s 3xTg mice were treated with
rivastigmine for 21 days and hippocampi dissected and snap frozen. Secreted fractions from the hippocampi samples were extracted using
detergent-free buffer or buffer with detergent. Reported statistics are from t test. Detergent-free extracts were assayed with western immunoblot and
ELISA while detergent-containing extracts were assayed with ELISA. a Western blot of sAPPα. b Western blot of sAPPt. c sAPPα levels. d sAPPt levels.
e Ratio of sAPPα to sAPPt. f Secreted (detergent-free) Aβ40 (sAβ40). g sAβ42. h Ratio of sAβ42 to sAβ40 + sAβ42. i Intracellular Aβ40 (iAβ40). j iAβ42.
k Ratio of iAβ42 to iAβ40 + iAβ42.

medication. sAPPβ levels dropped signiﬁcantly with
rivastigmine treatment (Fig. 6c). Ratios of sAPPα or
sAPPβ to sAPPt followed similar trends (Fig. 6d, e).
Brain levels of Aβ (1–40 and 42) were elevated overall in
AD subjects compared to non-AD controls (Fig. 6f, g).

However, there was no signiﬁcant difference in Aβ levels
when we compared those treated with rivastigmine vs.
nontreated AD patients (Fig. 6g, h). Effect sizes
(Hedge’s g) for pairwise comparisons are in Supplementary Table S4.
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Fig. 5 Changes induced by rivastigmine and TAPI in levels of different pro- and mature ADAM proteins and ADAM processing in human
cultures, interaction effects. Primary human brain (PHB) cultures were co-treated with rivastigmine and TAPI as described in the text. Figure shows
effects of rivastigmine and TAPI. Western immunoblotting was carried out on cell lysates to evaluate alterations of pro- and mature ADAM proteins
by rivastigmine treatment and TAPI treatment. Reported statistics are vs. log(dose + 1). a Western blotting showing different proteins. b pro-ADAM-9.
c pro-ADAM-10. d Mature ADAM-9. e Mature ADAM-10. f ADAM-9 processing, measured as mature ÷ (mature + pro). g ADAM-10 processing.

ADAM-10 may be a particularly inﬂuential α-secretase in
PHB

Correlation of biomarker levels (Supplementary Table
S5), revealed that both mature ADAM-9 and ADAM-10
levels signiﬁcantly (p ≤ 0.05, adjusted for multiple

comparisons by false discovery rate42) correlated with
any APP metabolite levels. ADAM-9 levels only signiﬁcantly correlated (r = −0.584) with Aβ40, while
ADAM-10 levels correlated signiﬁcantly with sAPPt
(r = 0.685), sAPPα (r = 0.834 or r = 0.849, Western and
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Fig. 6 (See legend on next page.)

ELISA), sAPPβ (r = −0.747), CTFβ (r = −0.691). In
addition, whereas levels of pro- and mature ADAM-9
correlated with each other (r = 0.595), correlation
between pro- and mature ADAM-10 levels (r = 0.555)
was not signiﬁcant.

Discussion
National Institutes of Health, USA (NIH) started an
initiative to test (https://grants.nih.gov/grants/guide/paﬁles/PAR-18-909.html) approved drugs with known safety
proﬁles for alternate treatments due to the multiple
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(see ﬁgure on previous page)
Fig. 6 Effects of rivastigmine in AD brain samples. Postmortem brain tissue (Brodmann Areas 21/22) extracts obtained from non-AD controls, AD
patients who were treated with rivastigmine, and AD patients who were given no drug treatments for AD were assayed by separate ELISAs for levels
of sAPPα, sAPPt, Aβ40, and Aβ42 in the secreted fraction. ANOVAs were followed by simultaneous pairwise comparisons. Reported p-values in ﬁgure
are for omnibus ANOVA. Pairwise comparisons were performed at α = 0.05. Groups sharing letters do not signiﬁcantly differ from each other at this
level of signiﬁcance. Effect sizes of pairwise differences are expressed as Hedge’s g. a sAPPt. b sAPPα. c sAPPβ. d sAPPα ÷ (sAPPα + sAPPβ). e sAPPβ ÷
(sAPPα + sAPPβ). f Secreted Aβ40. g Secreted Aβ42. h Aβ42 ÷ (Aβ40 + Aβ42). i Rivastigmine restoration of neuronal and synaptic viability and
function through realigning APP processing pathways. Bold, blue text indicates protein or peptide differences speciﬁcally reported in this paper.
Italicized text indicates cited pathways/factors. Rivastigmine has the effect of reducing BACE1 (β-secretase) levels92. In addition, it stimulates ERK and
Akt activation108. ERK, in particular, regulates the ADAM-9 and 10 α-secretase proteins93–95,109 and the SOX9 transcription factor98,99. SOX9 regulates
the proprotein convertase Furin97, which converts proADAM-9 and 10 into mature (active) forms96. Thus, rivastigmine activity results in enhancement
of levels of mature (active) α-secretase proteins. This enhancement combined with depression of β-secretase drives APP processing toward the “nonamyloidogenic” neuroprotective/neurotrophic pathway. Increase in neurotrophic APP cleavage products results in restoration or enhancement of
synaptic markers (such as synaptophysin), neuromorphology, and overall neuronal survival.

clinical beneﬁts of most chemical entities. It is, therefore,
important to undertake basic mechanistic studies of drugs
already approved for clinical use. Most drugs are studied
in different cellular and animal models, mostly transgenic
mice, and further mechanisticy study effectively stops if
the data yield desired results. Human AD trials also focus
on speciﬁc cognitive or institutionalization goals, and
upon achieving the desired outcomes, the focus shifts to
marketing and distributing the drug. There is generally
little post-approval followup to determine the effects of
the drugs on AD pathology, which forms the basis of its
progression. Given that at least Exelon is administered to
nearly every AD patient in the USA, it is critical to
understand long-term effects of the agent on patients'
brains and effects of cholinergic overload. This study
directly evaluates the brains of rivastigmine-treated AD
patients and AD patients not treated with any ChEI and
compares both to cognitively normal subjects.
In addition, anti-AD drugs are extensively studied in the
context of their “targets”, be they cholinergic systems,
NMDA, microtubule-associated protein tau, or Aβ.
Additional work may be done on effects on tau or Aβ, but
additional processing enzymes and metabolites are generally not also included in any reports, even if those effects
may play a role in disease progression. For example, the
ChEI (−)-Phenserine has APP and Aβ lowering properties
in cell culture, animal models20, and AD subjects21.
Donepezil elevates sAPPα and reduces Aβ in culture by
upregulating sorting nexin protein 33 (SNX33)22. Our
study is a comprehensive look at rivastigmine effects on
sAPPα and Aβ plus the α-secretases, ranging from cell
culture, rat brain, human primary brain cultures, and
adult human brains. Regarding such comprehensive
study, no other study has reported the effects of an antiAD drug at distant points along the lifespan, speciﬁcally
fetal brain-origin primary cultures and elderly subject
brains.
This study has revealed a potentially novel disease modifying activity for AD and did so through comprehensive

analysis of the Aβ biogenesis pathway and its yield. The
cholinesterase inhibiting effects of rivastigmine are valuable,
as it targets butyrylcholinesterase, which is increased in AD,
but they are short-term and temporary. Our study suggests
that rivastigmine’s “beneﬁcial side effects” may indicate its
utility in treating AD at earlier, prodromal stages, such as
MCI.
We demonstrated that rivastigmine promotes α-secretase processing by upregulating levels of ADAM-9, -10,
and -17, and the precursors of ADAM-10 and -17, as well
as sAPPα. This increase in processing by the nonamyloidogenic pathway accompanies a decline in levels
of sAPPβ, Aβ40, and Aβ42. Rivastigmine elevated sAPPα
and reduced potentially neurotoxic sAPPβ and Aβ at
concentrations as low as 100 nM, which, unlike prior
studies, has clinical relevance43. Notably, rivastigmineinduced activity was reversed by the addition of a nonselective ADAM inhibitor, TAPI. Further, TAPI without
rivastigmine resulted in signiﬁcantly elevated levels of
mature ADAM-9. However, it signiﬁcantly reduced levels
of mature ADAM-10. Human postmortem brain sAPPα
levels were also elevated in AD patients treated with rivastigmine, compared to untreated AD patients, which
conﬁrms elevation in sAPPα levels observed in PRBC
following rivastigmine treatment17. We have characterized a novel, potentially disease-modifying, function for
rivastigmine that may be independent of its anticholinesterase activities. Should this function exist in noncholinergic rivastigmine derivatives it may provide a
fruitful avenue of early pharmaceutical intervention
without the unwanted dose- limiting effects of cholinesterase modiﬁcation.
On its face, this appears to be untenable, given that the
comprehensive “Investigation Into Delay to Diagnosis of
Alzheimer’s Disease With Exelon” (InDDEx) study
reported no signiﬁcant beneﬁt of rivastigmine to delay
progression from MCI to AD44. However, stratiﬁcation of
the same study’s outcomes by gender revealed a signiﬁcant delay in progression for women treated with
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rivastigmine45. Furthermore, non-blind trial patient studies have shown greater efﬁcacy of early administration of
rivastigmine for women than for men46,47. In particular,
one such study examined anatomical changes in patient
brains and explicitly suggested that rivastigmine “treatment also signiﬁcantly reduced ventricular expansion,
whole-brain atrophy rate and white matter loss in female
BuChE wildtype animals, suggesting a possible diseasemodifying effect.” based on brain pathology difference46.
Mechanistic studies in animals showed that males eliminated rivastigmine 2.5 times more quickly than did
females48. Estrogen modiﬁes the processing of APP49. An
estrogen receptor 1 (ESR1) haplotype modiﬁed the
response to rivastigmine in a human study47. Animal
studies suggest that testosterone may also play a role.
Testosterone may interfere with rivastigmine entry into
the brain50, and greater clearance of rivastigmine in male
animals was attributed to testosterone48. Amelioration of
induced memory deﬁcits by rivastigmine differed by sex,
but this was altered by orchidectomy and not
ovariectomy51.
ChEIs are widely used to treat the symptoms of AD52,53,
with four agents (tacrine, donepezil, rivastigmine, and
galantamine) approved by the U.S. FDA and the European
Medicines Agency (EMA). Each of these ChEIs varies
from one another in how they inhibit ChE, and in their
pharmacokinetics, safety, and long-term efﬁcacy54. Furthermore, selective butyrylcholinesterase inhibition
increased brain acetylcholine, augmented learning, and
reduced Aβ peptide in rodents. This suggests that reversible inhibition of brain BChE could represent a treatment
of AD, improving cognition and modulating neuropathological markers of AD.
A hypothesis for AD pathogenesis posits a shift in the
processing of APP towards the amyloidogenic route or a
decline in Aβ brain clearance that causes excessive
accumulation of Aβ, and/or a shift in the ratio of Aβ
species to favor the Aβ42 form55, although further truncated forms of Aβ may also play a role56,57. The reported
upregulation of BACE1 during aging and AD may partly
underlie this brain change58–60. There is support for a
decline in α-secretase activity during AD. Reductions in
CSF sAPPα levels exist in sporadic as well as nonsporadic
AD61,62, and positive correlations exist between declines
sAPPα levels and reduced cognitive performance in AD
subjects62 and normal aged rats63. However, other studies
have reported unchanged levels of sAPPα in CSF during
sporadic AD64–67, with decreases only evident in
advanced AD67; suggesting a need for further evaluation
concerning disease staging68. sAPPα possesses neurotrophic and neuroprotective actions across cellular and
in vivo models68. Thus, augmenting brain sAPPα levels
has become a therapeutic strategy across neurodegenerative disorders61,69
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Our study builds on previous ﬁndings suggesting that
ChEIs can possess APP-modulating properties70. As an
example, the acetyl-ChEI phenserine dose-dependently
reduces the synthesis of total APP post-transcriptionally,
via an iron regulatory element in the 5′−untranslated
region (UTR) of APP mRNA19,20. In contrast, other ChEIs
such as (−)−physostigmine lack action on APP71.
To evaluate the translational relevance of these cell
culture ﬁndings in an in vivo system, we treated 3×Tg AD
model mice with rivastigmine with a clinically relevant
dose equivalent to approximately 5 mg rivastigmine for an
80 kg human, following normalization of body surface
area between species, in line with FDA guidelines72. A
signiﬁcant rise in brain levels of sAPPα resulted, accompanied by a decrease in Aβ40 and 42.
We quantiﬁed sAPPα levels in postmortem human brain
samples obtained from AD subjects who had been administered rivastigmine and compared these to samples from
patients who did not receive any ChEI drug. Notably, we
observed higher levels of sAPPα in the secreted fraction of
brain samples from subjects exposed to rivastigminewithout a reduction in Aβ. Such failure to see changes in
Aβ levels in late-stage AD upon rivastigmine treatment is
readily explained by the large Aβ accumulation over years
or decades, which may mask any changes in Aβ production. A complete shut off of all Aβ production would be
unlikely to quickly produce an accompanying reduction in
measured Aβ levels in the brain, even if Aβ clearance
mechanisms functioned at normal levels, and in AD, Aβ
clearance is impaired73.
sAPPα is neurotrophic74–82. The intraventricular
administration of sAPPα enhances memory function of
mice83, and sAPPα mediates numerous APP-mediated
actions on brain development and cognition68,74,84–86. A
mutation within the α-secretase cleavage site of human
APP (APP770K687N) leads to reduced sAPPα production
and elevation of Aβ and causes early onset dementia87.
Activity-attenuating mutations within the prodomain of
human ADAM-10 gene link to AD88,89. It is noteworthy,
therefore, that in AD mouse models, rivastigmine treatment reduced Aβ-related brain pathology90 and cognitive
dysfunction, speciﬁcally related to Aβ load91.
Rivastigmine nanoformulations signiﬁcantly inhibit
BACE1 mRNA levels, which may, in turn, increase APP
processing via the α-secretase pathway92. We show,
herein, that rivastigmine treatment increases levels of
ADAM-9 and ADAM-10. Among potential stimulatory
pathways induced by rivastigmine, ADAM-10 transcription is elevated by altering extracellular signal-related
kinase (ERK) 1/2 phosphorylation93,94. Inhibition of ERK
reduces activity of ADAM-995. The ADAM proproteins
are processed by the proprotein convertase furin96. Furin
is regulated by transcription factor SOX997. SOX9 is
regulated by the MAPK/ERK pathway98, including the
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participation of ERK99. We propose, therefore, a testable
and mechanistic pathway for the non-ChEI-mediated
neuroprotective and neurotrophic activity of rivastigmine
(Fig. 6i). Several elements of this model are not explicitly
tested in the current study. We are proposing a hypothesis
based on our work along with others’ in the ﬁeld.
Another activity of APP is its contribution to Fe (iron)
homeostasis in neuronal cells100–103. In particular, this
operates through a site in the APP 5′-UTR that binds iron
response protein 1 (IRP1)100,101,103, interleukin 1
(IL1)102,104,105, and microRNA-346100. This “FeAR (Fe,
APP, RNA) nexus” may also play a feedback role in αsecretase processing of APP, given that Fe also modulates
α-secretase cleavage of APP106, speciﬁcally to increase
sAPPα cellular retention and inhibit BACE1 activity107.
Rivastigmine alters activity of α- and β-secretases. It
reduces β-secretase through an unknown mechanism92.
However, rivastigmine nanoformulation can produce
signiﬁcant inhibition in mRNA levels of BACE192. Rivastigmine stimulates the activation of both ERK and
Akt108. ERK regulates ADAM-9, -10, and -17 at multiple
levels93–95,109 and regulates transcription factor
SOX998,99. SOX9 regulates Furin97, which processes the
ADAM-9, -10, and -17 proproteins96, although we only
found rivastigmine stimulation of proADAM-9 cleavage.
Ultimately, levels of the mature α-secretases increase,
corresponding to increased α-secretase activity. The
combination of reduced β- and enhanced α-secretase
drives APP processing toward neurotrophic/protective
sAPPα and related products. These could stimulate
restoration of synaptic markers, such as synaptophysin,
and maintain and promote healthy neuromorphology and
neurosurvival17,18,68,80,83.
Rivastigmine is a ChEI. Its administration is expected to
result in net increases in acetylcholine (and butyrylcholine)14,110. Acetylcholine stimulates nicotinic and muscarinic receptors, and such stimulation further stimulates
α-secretase activity and reduces Aβ production111. Thus,
an M1-receptor pathway may explain our ﬁndings. In
particular, the M1 receptor agonists AF102B or dicyclomine resulted in activation of PKCα and ERK, resulting in
increased levels of ADAM-17 and a shift in APP processing toward the non-amyloidogenic pathway112. However,
treatment of primary cortical neurons with the M1 agonist carbachol did not alter levels of ADAM-10, ADAM17, or BACE1 in their brains113, and M1 receptor
knockout likewise did not alter ADAM-10 or ADAM-17
levels113. The neuroprotective extract of Withania somnifera root reversed effects of a scopolamine memory loss
model114 and operated through the M1 receptor115. While
we propose an M1-independent model, we understand
that a cholinergic alternative may exist.
Thus far, all Aβ-based clinical trials for AD treatment
have failed. Would this mean rivastigmine’s potential
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disease-modifying activity is foredoomed as a treatment?
We would say it is still viable because (1) those Aβ-related
treatments that have failed in clinical trial were administered after amyloid plaque accumulation, when plaque
may have reached a point wherein clearance mechanisms
were simply no longer up to the task. In addition, AD
brains accumulate Aβ, tau, and a number of other proteins, suggesting the failure of shared protein turnover
pathways4,116. However, pathogenesis of AD is now
recognized as beginning well before obvious “pathology”
can be detected117–119. In addition, the potential diseasemodifying activity of rivastigmine may be due not so
much to reduction of Aβ but stimulation of neurotrophic
sAPPα production and other effects of ADAM proteins.
Any accompanying Aβ reduction may be a fortuitous
happenstance. On the other hand, rivastigmine’s potential
disease-modifying activity could be due both to cholinergic and non-cholinergic pathway modiﬁcations, making it a “one-drug cocktail”.
In conclusion, we have evaluated the impact of rivastigmine on APP processing across neuronal cell lines and
primary mixed cell human brain cultures, within the
hippocampus of a well-characterized AD animal mouse
model (3×Tg mice), and in human postmortem brain
tissue. The mouse dosing we used was several times that
currently used for humans (4–5 times transdermal dose,
9–11 times oral dose, mg/kg basis). Nevertheless, it is a
commonly-used dose for animal studies91,120. Efﬁcacy and
side effects must be titrated for each individual species.
We consistently observed evidence that rivastigmine
treatment associated with α-secretase activity: Elevated
levels of the active forms of ADAM-9, -10, and -17, as well
as sAPPα. If appropriately optimized and harnessed, this
drug activity could impact Alzheimer’s disease progression via a drug whose tolerability and efﬁcacy is already
established for the symptomatic treatment of AD.
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